Cited by 4,319Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and StudiesRenal cell carcinoma treatment

The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Open access

Reig, Maria, Forner, Alejandro, Rimola, Jordi, Ferrer-Fàbrega, Joana, Burrel, Marta, Garcia-Criado, Ángeles, Kelley, Robin K., Galle, Peter R., Mazzaferro, Vincenzo, Salem, Riad, Sangro, Bruno, Singal, Amit G., Vogel, Arndt, Fuster, Josep, Ayuso, Carmen, Bruix, Jordi·2022·Journal of Hepatology

DOI 10.1016/j.jhep.2021.11.018PMC PMC8866082

Open this paper in CoChat — free account Open PDF

Abstract

There have been major advances in the armamentarium for hepatocellular carcinoma (HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and treatment strategy published in 2018. Whilst there have been advances in all areas, we will focus on those that have led to a change in strategy and we will discuss why, despite being encouraging, data for select interventions are still too immature for them to be incorporated into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that are required to make clinical decisions for individual patients, considering all of the parameters that must be considered to deliver personalised clinical management.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2021.11.018

Cites

136 of 136 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citation
Preoperative assessment of liver function: a comparison of 99mTc‐Mebrofenin scintigraphy with indocyanine green clearance test
Erdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,656
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citation
Transection of the oesophagus for bleeding oesophageal varices
Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C., & Williams, R. (1973) · Journal of British Surgery · doi:10.1002/bjs.1800600817 · Cited by 7,941
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citation
Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S. A., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,173
Self-citation
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,974
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Hepatocellular carcinoma
Forner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,774
Self-citation
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586

Show all 136 references

Sorted by citations

Items 401–500 of 1,000

hnRNPA2B1 promotes the occurrence and progression of hepatocellular carcinoma by downregulating PCK1 mRNA via a m6A RNA methylation manner
Hao, W., Chen, Z., Tang, J., Ru, Y., Gao, W., & Xu, H. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04704-4 · Cited by 24
Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part II – Non-surgical treatments
Cabibbo, G., Daniele, B., Borzio, M., Gardini, A. C., Cillo, U., Colli, A., Conforti, M., Dadduzio, V., Dionisi, F., Farinati, F., et al. (2023) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.10.028 · Cited by 22
Direct interaction of platelet with tumor cell aggravates hepatocellular carcinoma metastasis by activating TLR4/ADAM10/CX3CL1 axis
Gao, J.-H., He, A., Liu, L.-M., Zhou, Y.-J., Guo, Y.-W., Meng, L., Zeng, X., Gong, X., Lu, Y., Liang, H., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216674 · Cited by 23
Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma
Ho, C.-T., Tan, E. C., Lee, P., Chu, C., Huang, Y., Huo, T., Su, Y., Hou, M., Wu, J., & Su, C. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0103 · Cited by 23
Systemic immune-inflammation index and the survival of hepatocellular carcinoma patients after transarterial chemoembolization: a meta-analysis
Li, D., Zhao, X., Pi, X., Wang, K., & Song, D. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00889-y · Cited by 24
Radiation Major Hepatectomy Using Ablative Dose Yttrium-90 Radioembolization in Patients with Hepatocellular Carcinoma 5 cm or Larger
Choi, J. W., Suh, M., Paeng, J. C., Kim, J. H., & Kim, H. (2023) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2023.10.011 · Cited by 22
Computational Modeling of Thermal Ablation Zones in the Liver: A Systematic Review
van Erp, G. C. M., Hendriks, P., Broersen, A., Verhagen, C. A. M., Gholamiankhah, F., Dijkstra, J., & Burgmans, M. C. (2023) · Cancers · doi:10.3390/cancers15235684 · Cited by 22
“Percutaneous thermal ablation is an established minimally invasive treatment for primary and secondary liver tumors [1,2].”
Background
A Novel Coacervate Embolic Agent for Tumor Chemoembolization
Liu, M., Sun, Y., Zhou, Y., Chen, Y., Yu, M., Li, L., Yan, L., Yuan, Y., Chen, J., Zhou, K., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304488 · Cited by 22
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
Wu, M. C., Fulgenzi, C. A. M., D’Alessio, A., Cortellini, A., Celsa, C., Manfredi, G. F., Stefanini, B., Wu, L. Y., Huang, Y., Saeed, A., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101232 · Cited by 22
Self-citation
HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion
Tang, S., Shi, F., Xiao, Y., Cai, H., Ma, P., Zhou, Y.-M., Wu, Z., Chen, S., & Guo, W. (2025) · Hepatology International · doi:10.1007/s12072-024-10762-7 · Cited by 22
“…West and East regarding the treatment of advanced HCC patients with PVTT, as systemic therapies are recommended as the preferred option in the West [18], while radically locoregional approaches, such as transarterial chemoembolization (TACE) and even surgical resection, have been recommended as…”
Clinical Applications of Artificial Intelligence (AI) in Human Cancer: Is It Time to Update the Diagnostic and Predictive Models in Managing Hepatocellular Carcinoma (HCC)?
Romeo, M., Dallio, M., Napolitano, C., Basile, C., Nardo, F. D., Vaia, P., Iodice, P., & Federico, A. (2025) · Diagnostics · doi:10.3390/diagnostics15030252 · Cited by 25
“…at improving the prognosis of HCC patients, major efforts have been made to characterize an adequate surveillance program, providing early identification of the disease for recognized high-risk individuals, thus ensuring a larger range of “curative”/“resolutive” therapeutic opportunities [26].”
Influential
Microrobotic Swarms for Cancer Therapy
Xie, L., Liu, J., Yang, Z., Chen, H., Wang, Y., Du, X., Fu, Y., Song, P., & Yu, J. (2025) · Research · doi:10.34133/research.0686 · Cited by 22
Systemic treatment in patients with hepatocellular carcinoma and advanced liver dysfunction
Pinter, M., Fulgenzi, C. A. M., Pinato, D. J., & Scheiner, B. (2025) · Gut · doi:10.1136/gutjnl-2025-334928 · Cited by 23
“2 Indeed, a recently presented retrospective multicentre study suggested a survival benefit in patients with HCC and chronic hepatitis C who underwent direct-acting antiviral treatment concomitantly with immunotherapy.”
WNT–β-catenin signalling in hepatocellular carcinoma: from bench to clinical trials
Lehrich, B. M., & Monga, S. P. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01127-y · Cited by 27
“radiofrequency or microwave ablation, liver resection or transplantation, are curative, improving 5-year survival to >60% 10 .”
Efficacy and Safety of Regorafenib with or without PD-1 Inhibitors as Second-Line Therapy for Advanced Hepatocellular Carcinoma in Real-World Clinical Practice
Liu, K., Wu, J., Xu, Y., Li, D., Huang, S., & Ye, M. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s383685 · Cited by 22
Cancer Immunology: Impact of Radioembolization of Hepatocellular Carcinoma on Immune Response Modulation
Torkian, P., Haghshomar, M., Farsad, K., Wallace, S., Golzarian, J., & Young, S. J. (2023) · American Journal of Roentgenology · doi:10.2214/ajr.22.28800 · Cited by 22
Advances in post-operative prognostic models for hepatocellular carcinoma
He, Z., She, X., Liu, Z., Gao, X., Lu, L., Huang, J., Lu, C. C., Lin, Y., Liang, R., & Ye, J. (2023) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200067 · Cited by 22
“In December 2021, Reig et al. (2022) gave a major update to the BCLC staging and released the latest version, that is, the 2022 version of the BCLC staging.”
Background
Role of palliative SBRT in barcelona clinic liver cancer-stage C hepatocellular carcinoma patients
Sharma, D., Thaper, D., Kamal, R., & Yadav, H. P. (2023) · Strahlentherapie und Onkologie · doi:10.1007/s00066-023-02065-x · Cited by 22
“As per BCLC updated version 2022, the treatment of choice for such a category is Immunotherapy± systemic therapy [12].”
BackgroundMethod
The prognostic role of the AST/ALT ratio in hepatocellular carcinoma patients receiving thermal ablation combined with simultaneous TACE
Wang, F., Gao, S., Wu, M., Zhao, D., Sun, H., Sothea, Y., Chen, Y., Zhang, Z., Yang, M., Dong, Y. W., et al. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02719-1 · Cited by 22
“The main HCC treatments include surgical resection, liver transplantation, ablation, transarterial chemoembolization (TACE), and systemic treatment [2].”
BackgroundMethod
Current Status of Management of Hepatocellular Carcinoma in The Gulf Region: Challenges and Recommendations
Albarrak, J., & Al-Shamsi, H. O. (2023) · Cancers · doi:10.3390/cancers15072001 · Cited by 24
“The 2022 Barcelona Clinic Liver Cancer (BCLC) staging and treatment strategy highlighted the different concepts and parameters that physicians and multidisciplinary tumor boards should integrate for a personalized approach to treating HCC (Figure 2) [68].”
BackgroundInfluential
Radioembolization for Treatment of Hepatocellular Carcinoma: Current Evidence and Patterns of Utilization
Briody, H., Duong, D., Yeoh, S. W., Hodgson, R., Yong, T. L., Hannah, A., Lee, M. J., Leong, S., Maingard, J. T., Asadi, H., et al. (2023) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2023.03.020 · Cited by 22
Analysis of Sonazoid contrast-enhanced ultrasound for predicting the risk of microvascular invasion in hepatocellular carcinoma: a prospective multicenter study
Yao, J., Li, K., Yang, H., Lu, S., Ding, H., Luo, Y., Li, K., Xie, X., Wu, W. K., Jing, X., et al. (2023) · European Radiology · doi:10.1007/s00330-023-09656-3 · Cited by 22
“Surgical resection, liver transplantation, and ablation are potentially curative for BCLC 0&A stage [2].”
Background
Systemic treatment in patients with Child–Pugh B liver dysfunction and advanced hepatocellular carcinoma
Costa, F. P., Wiedenmann, B. J., Roderburg, C., Mohr, R. U., & Abou‐Alfa, G. K. (2023) · Cancer Medicine · doi:10.1002/cam4.6033 · Cited by 23
The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma – A systematic review
Meyers, B. M., Knox, J. J., Liu, D. M., McLeod, D., Ramjeesingh, R., Tam, V. C., & Lim, H. J. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102584 · Cited by 21
Radiologic Patterns Determine the Outcomes of Initial and Subsequent Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma
Hung, Y., Lee, I., Chi, C., Lee, R., Liu, C., Chiu, N., Hwang, H.-E., Chao, Y., Hou, M., & Huang, Y. (2023) · Liver Cancer · doi:10.1159/000530950 · Cited by 22
Drug-Off Criteria in Patients with Hepatocellular Carcinoma Who Achieved Clinical Complete Response after Combination Immunotherapy Combined with Locoregional Therapy
Kudo, M. (2023) · Liver Cancer · doi:10.1159/000532023 · Cited by 22
Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab
Okuno, M., Ishii, T., Ichida, A., Soyama, A., Takemura, N., Hirono, S., Eguchi, S., Hasegawa, K., Sasaki, Y., Uemura, K., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11302-6 · Cited by 22
“Potential curative therapies such as resection, liver transplantation, and local ablation for early-stage HCC and transarterial chemoembolization (TACE) for intermediate-stage HCC have been adopted as the standard of care according to several clinical practice guidelines [2, 3].”
BackgroundMethod
Hepatocellular carcinoma surveillance in Australia: current and future perspectives
Hui, S., Bell, S., Le, S. T. T., & Dev, A. T. (2023) · The Medical Journal of Australia · doi:10.5694/mja2.52124 · Cited by 23
Transplant oncology – Current indications and strategies to advance the field
Krendl, F. J., Bellotti, R., Sapisochín, G., Schaefer, B., Tilg, H., Scheidl, S. J., Margreiter, C., Schneeberger, S., Oberhuber, R., & Maglione, M. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100965 · Cited by 22
“35,48 53 Yet, since applying downstaging entry criteria will inevitably lead to the exclusion of patients who might bene ﬁ t from downstaging some suggest offering downstaging to all patients outside of existing transplant criteria (all-comers) as long as no extrahepatic disease and no…”
BackgroundMethod
Transarterial chemoembolization combined donafenib with/without PD-1 for unresectable HCC in a multicenter retrospective study
Li, H., Wang, J., Zhang, G., Kuang, D., Li, Y., He, X., Cheng, X., Wang, Y., Shi, M., Han, X., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1277329 · Cited by 23
“The most common AEs of the triple combination modality were fever, abdominal pain, and liver function damage related to TACE (12, 13); hypertension, diarrhea, and HFSR related to TKIs (7, 13) and rash, fatigue, and pruritus related to PD-1 inhibitors (3, 24, 25).”
Background
A Grading System of Microvascular Invasion for Patients with Hepatocellular Carcinoma Undergoing Liver Resection with Curative Intent: A Multicenter Study
Wang, H., Chen, J., Yin, S.-Y., Sheng, X., Wang, H., Lau, W. Y., Dong, H. F., & Cong, W. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s447731 · Cited by 22
A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Han, J. W., Lee, S. K., Kwon, J. H., Nam, S. W., Yang, H., Bae, S. H., Kim, J. H., Nam, H., Kim, C. W., Lee, H. L., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3978 · Cited by 22
Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice
Shimose, S., Saeki, I., Tomonari, T., Ito, T., Tani, J., Takeuchi, Y., Yoshioka, N., Naito, T., Takeuchi, M., Kakizaki, S., et al. (2024) · Oncology Letters · doi:10.3892/ol.2024.14530 · Cited by 22
Adjuvant immunotherapy improves recurrence-free and overall survival following surgical resection for intermediate/advanced hepatocellular carcinoma a multicenter propensity matching analysis
Xu, X., Wang, M.-D., Xu, J.-H., Fan, Z., Diao, Y., Chen, Z., Jia, H., Liu, F., Zeng, Y., Wang, X., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1322233 · Cited by 22
Locoregional therapies for hepatocellular carcinoma: The current status and future perspectives
Chen, J., Jin, Z., Zhong, B., Fan, W., Zhang, W., Luo, B., Wang, Y., Teng, G., & Zhu, H. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12554 · Cited by 21
Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: A multi-center cohort study
Huang, Z., Chen, T., Li, W., He, W. A., Liu, S., Wu, Z., Li, B., Yuan, Y., & Qiu, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112711 · Cited by 21
Targeted therapies in hepatocellular carcinoma: past, present, and future
Gujarathi, R., Franses, J. W., Pillai, A., & Liao, C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1432423 · Cited by 22
“Certain patients with BCLC stage B who undergo treatment with effective downstaging strategies can potentially be eligible for liver transplantation (7).”
Background
The prognostic value of systemic immune-inflammation index in patients with unresectable hepatocellular carcinoma treated with immune-based therapy
Tian, H., Xu, B., Wang, L.-N., Wang, Z., Shi, H.-C., Zhong, C., Zhu, X.-D., Shen, Y., Zhou, J., Fan, J., et al. (2025) · Biomarker Research · doi:10.1186/s40364-024-00722-6 · Cited by 23
Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial
Zhu, H., Fan, W., Zhao, C., Wang, S., Li, Y., Zhi-Cheng, J. I. N., Zhang, Z.-W., Guo, J.-H., Cheng, H.-T., Zhang, Q., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-01796 · Cited by 25
“In addition, a higher proportion of patients in the TACE group experienced BCLCp-C2 progression (new extrahepatic lesions and/or vascular invasion), 24 which further supports the use of combination strategies in patients with high tumor burden and aggressive disease characteristics.”
Immunotherapy-Based Treatments of Hepatocellular Carcinoma: AJR Expert Panel Narrative Review
Cannella, R., Lewis, S. C., da Fonseca, L. G., Ronot, M., & Rimola, J. (2022) · American Journal of Roentgenology · doi:10.2214/ajr.22.27633 · Cited by 21
Self-citation
Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?
Lee, C., Chan, S., & Chon, H. (2022) · Cancers · doi:10.3390/cancers14133213 · Cited by 19
Extending Surgical Resection for Hepatocellular Carcinoma Beyond Barcelona Clinic for Liver Cancer (BCLC) Stage A: A Novel Application of the Modified BCLC Staging System
Wee, I. J. Y., Moe, F. N. N., Sultana, R., Ang, R. W., Quek, P., Goh, B. K. P., Chan, C. Y., Cheow, P. C., Chung, A. Y., Jeyaraj, P. R., et al. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s370212 · Cited by 21
A comprehensive preoperative predictive score for post-hepatectomy liver failure after hepatocellular carcinoma resection based on patient comorbidities, tumor burden, and liver function: the CTF score
Alaimo, L., Endo, Y., Lima, H. A., Moazzam, Z., Shaikh, C. F., Ruzzenente, A., Guglielmi, A., Ratti, F., Aldrighetti, L. A., Marques, H. P., et al. (2022) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-022-05451-5 · Cited by 21
Variations in Textbook Oncologic Outcomes After Curative-Intent Resection: Early Versus Intermediate Hepatocellular Carcinoma Based on Barcelona Clinic Liver Cancer Criteria and Child-Pugh Classification
Moazzam, Z., Alaimo, L., Endo, Y., Lima, H. A., Shaikh, C. F., Ratti, F., Marques, H. P., Cauchy, F., Lam, V. W. T., Poultsides, G. A., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12832-2 · Cited by 21
Complete tumor necrosis confirmed by conversion hepatectomy after atezolizumab–bevacizumab treatment for advanced-stage hepatocellular carcinoma with lung metastasis
Fukunaga, A., Takata, K., Itoh, S., Yamauchi, R., Tanaka, T., Yokoyama, K., Shakado, S., Kohashi, K., Yoshizumi, T., & Hirai, F. (2022) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-022-01744-z · Cited by 21
“The combined therapy of atezolizumab (programmed cell death ligand 1 antibody) and bevacizumab (vascular endothelial growth factor antibody) (atezo/bev) is currently the first-line treatment for advanced-stage and some intermediate-stage HCCs [2, 3].”
Background
Efficacy and safety of different options for liver regeneration of future liver remnant in patients with liver malignancies: a systematic review and network meta-analysis
Yi, F., Zhang, W., & Feng, L. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02867-w · Cited by 21
“Introduction Surgical resection remains the most critical potentially curative treatment for patients with primary liver cancer or metastatic liver malignancies [1, 2].”
Background
Self-supervised learning-based Multi-Scale feature Fusion Network for survival analysis from whole slide images
Li, L. K., Liang, Y., Shao, M., Lu, S., Liao, S., & Ouyang, D. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.106482 · Cited by 21
Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma
Laface, C., Ranieri, G., Maselli, F. M., Ambrogio, F., Foti, C., Ammendola, M., Laterza, M., Cazzato, G., Memeo, R., Mastrandrea, G., et al. (2023) · Cancers · doi:10.3390/cancers15030654 · Cited by 21
Entecavir versus tenofovir on prognosis of hepatitis B virus‐related hepatocellular carcinoma after curative hepatectomy
Kao, W., Tan, E. C., Lee, H., Huang, Y., Huo, T., Chang, C., Chiou, J., Hou, M., Wu, J., & Su, C. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17438 · Cited by 19
“In addition, two sensitivity analyses were conducted: (1) excluded those patients who received interferon, ribavirin, lamivudine, adefovir and telbivudine; (2) excluded patients with BCLC stage B was conducted to examine the robustness of the results.”
Method
FAIL-T (AFP, AST, tumor sIze, ALT, and Tumor number): a model to predict intermediate-stage HCC patients who are not good candidates for TACE
Kaewdech, A., Sripongpun, P., Assawasuwannakit, S., Wetwittayakhlang, P., Jandee, S., Chamroonkul, N., & Piratvisuth, T. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1077842 · Cited by 21
KASL clinical practice guidelines for management of autoimmune hepatitis 2022
(2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0087 · Cited by 24
Patient-derived models facilitate precision medicine in liver cancer by remodeling cell-matrix interaction
Chen, K., Li, Y., Wang, B., Yan, X., Tao, Y., Song, W., Xi, Z., He, K., & Xia, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1101324 · Cited by 22
The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
Chan, L. L., & Chan, S. L. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0114 · Cited by 21
Radionuclide‐Labeled Microspheres for Radio‐Immunotherapy of Hepatocellular Carcinoma
Yang, S., Mu, C., Liu, T., Pei, P., Shen, W., Zhang, Y., Wang, G., Chen, L., & Yang, K. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300944 · Cited by 21
Predicting post-resection recurrence by integrating imaging-based surrogates of distinct vascular patterns of hepatocellular carcinoma
Meng, X., Tang, T., Zhou, Y., Xia, C., Xia, T., Shi, Y., Long, X., Liang, Y., Xiao, W., Wang, Y., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100806 · Cited by 23
Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study
Zhao, C., Xiang, Z., Li, M., Wang, H., Liu, H., Yan, H., & Huang, M. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s418256 · Cited by 21
“We originally deduced that the former might be more effective because the REFLECT trial did not demonstrate significant difference in OS between LEN treatment and sorafenib,22 while Atezo/Bev was shown to provide better survival benefits compared to sorafenib.12 However, other large multicenter retrospective studies h…”
BackgroundInfluential
Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma
Zanuso, V., Pirozzi, A., Balsano, R., Pressiani, T., & Rimassa, L. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s347932 · Cited by 21
“Systemic treatment is indicated for patients with advanced or intermediate HCC that are unsuitable for locoregional treatment and with preserved liver function.(1,3) After more than a decade of multi-kinase inhibitors (MKIs) monopoly, in 2020, the combination of atezolizumab plus bevacizumab became the new first-line…”
Background
Proportion of Time Covered by Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis
Daher, D., Dahan, K. S. E., Yekkaluri, S., Gopal, P., Rich, N. E., Parikh, N. D., Murphy, C. C., & Singal, A. G. (2023) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002596 · Cited by 21
Self-citation
New and Old Key Players in Liver Cancer
Cuesta, Á. M., Palao, N., Bragado, P., Gutiérrez-Uzquiza, Á., Herrera, B. M., Sánchez, A., & Porrás, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417152 · Cited by 23
“Different options for ﬁrst-, second-and subsequent line treatments are currently available, such as combinations of immunotherapy with tyrosine kinase inhibitors (TKIs) or antiangiogenic agents (e.g., vascular endothelial growth factor (VEGF) inhibitors) [16,17].”
Background
Locoregional Therapies for Hepatocellular Carcinoma prior to Liver Transplant: Comparative Pathologic Necrosis, Radiologic Response, and Recurrence
Mosenthal, M., Adams, W., Cotler, S. J., Ding, X., Borge, M. A., Malamis, A. P., Lee, D. D., Thomas, T. O., Jawahar, A., Amin, P., et al. (2023) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2023.12.009 · Cited by 24
Bioinspired Tumor Calcification‐Guided Early Diagnosis and Eradication of Hepatocellular Carcinoma
Bai, S., Chen, H., Fu, S., Liu, L., Gao, X., Li, S., Chen, Y., Lan, Y., Xia, Y., Dai, Q., et al. (2024) · Advanced Materials · doi:10.1002/adma.202310818 · Cited by 21
Atezolizumab plus bevacizumab as a downstaging therapy for liver transplantation in hepatocellular carcinoma with portal vein thrombosis: The first report
Kumar, P., Krishna, P., Nidoni, R., Adarsh, C. K., Arun, M., Shetty, A., Mathangi, J., Sandhya, S., Gopasetty, M., & Venugopal, B. (2024) · American Journal of Transplantation · doi:10.1016/j.ajt.2024.01.007 · Cited by 21
Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Kudo, M. (2024) · Liver Cancer · doi:10.1159/000540801 · Cited by 24
Safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria
Li, L., Xu, X., Wang, W., Huang, P., Yu, L., Ren, Z., Fan, J., Zhou, J., Zhang, L., & Wang, Z. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010035 · Cited by 21
Mesolithic Europe : glimpses of another world
Spikins, P. (2008) · White Rose Research Online (University of Leeds, The University of Sheffield, University of York) · Cited by 21
Lipid metabolism of hepatocellular carcinoma impacts targeted therapy and immunotherapy
Feng, X.-C., Liu, F., Chen, W.-Y., Du, J. T., & Liu, H. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i4.617 · Cited by 21
Advancing Surveillance Strategies for Hepatocellular Carcinoma: A New Era of Efficacy and Precision
Singal, A. G., Ng, M., & Kulkarni, A. L. (2024) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2024.101448 · Cited by 22
Self-citation
Effect of metformin on hepatocellular carcinoma patients with type II diabetes receiving transarterial chemoembolization: a multicenter retrospective cohort study
Chen, L., Wu, L., Zhang, L., Sun, B., Wu, W., Yu, L., Zhu, L., Sun, T., Liang, B., Zhao, H., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001872 · Cited by 20
Hepatic arterial infusion chemotherapy plus camrelizumab and apatinib for advanced hepatocellular carcinoma
Zuo, M., Cao, Y., Yang, Y., Zheng, G., Li, D., Shao, H., Ma, Q., Song, P., An, C., & Li, W. (2024) · Hepatology International · doi:10.1007/s12072-024-10690-6 · Cited by 22
“Conventional TACE (cTACE) using lipiodol mixed with chemotherapeutics is recommended as the first-line treatment in intermediate-stage HCC [5].”
Background
Using Voxel-Based Dosimetry to Evaluate Sphere Concentration and Tumor Dose in Hepatocellular Carcinoma Treated with Yttrium-90 Radiation Segmentectomy with Glass Microspheres
Sandow, T. A., Gimenez, J. M., Núñez, K., Tramel, R., Gilbert, P., Oliver, B., Cline, M. R., Fowers, K. D., Cohen, A. J., & Thevenot, P. (2024) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2024.05.020 · Cited by 20
Value of HCC surveillance in a landscape of emerging surveillance options: Perspectives of a multi-stakeholder modified Delphi panel
Singal, A. G., Quirk, L., Boike, J. R., Chernyak, V., Feng, Z., Giamarqo, G., Kanwal, F., Ioannou, G. N., Manes, S., Marrero, J. A., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001203 · Cited by 20
Self-citation
Systemic inflammatory response markers improve the discrimination for prognostic model in hepatocellular carcinoma
Rocco, A., Sgamato, C., Pelizzaro, F., Simeon, V., Coccoli, P., Compare, D., Pinto, E., Palano, G., Foschi, F. G., Raimondo, G., et al. (2025) · Hepatology International · doi:10.1007/s12072-025-10806-6 · Cited by 25
Hepatocellular carcinoma in patients without cirrhosis
Sato‐Espinoza, K., Valdivia-Herrera, M., Chotiprasidhi, P., & Ferrer, J. D. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i23.107100 · Cited by 24
“The BCLC system, originally developed for patients with chronic LD, particularly cirrhosis[87], was updated in 2022 to incorporate features more applicable to non-cirrhotic individuals[88].”
Performance of GALAD, GAAD, and ASAP for Early HCC Detection in Chronic Liver Disease: A Systematic Review and Meta-Analysis
Jarrah, M., Arvind, A., Gopal, P., Deodhar, S., Yang, J. D., Parikh, N. D., & Singal, A. G. (2025) · Liver Cancer · doi:10.1159/000547895 · Cited by 23
Self-citation
Improving surgical treatments for hepatocellular carcinoma
Malik, A. K., Geh, D., Evans, T. R. J., Chow, P. K. H., Mann, D. A., & White, S. A. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01143-y · Cited by 24
Metabolic Reprogramming and Its Relationship to Survival in Hepatocellular Carcinoma
Wang, Q., Tan, Y., Jiang, T., Wang, X., Li, Q., Li, Y., Dong, L., Liu, X., & Xu, G. (2022) · Cells · doi:10.3390/cells11071066 · Cited by 20
Outcome of liver cancer patients with SARS‐CoV‐2 infection: An International, Multicentre, Cohort Study
Muñoz, S., Sapena, V., Forner, A., Bruix, J., Sanduzzi‐Zamparelli, M., Ríos, J., Bouattour, M., El‐Kassas, M., Leal, C. R. G., Mocan, T., et al. (2022) · Liver International · doi:10.1111/liv.15320 · Cited by 19
Self-citation
Advances in Targeted Immunotherapy for Hepatobiliary Cancers
Ruff, S. M., Shannon, A. H., & Pawlik, T. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213961 · Cited by 21
Liver Transplantation after Successful Downstaging of a Locally Advanced Hepatocellular Carcinoma with Systemic Therapy
Schmiderer, A., Zoller, H., Niederreiter, M., Effenberger, M., Oberhuber, G., Krendl, F. J., Oberhuber, R., Schneeberger, S., Tilg, H., & Djanani, A. M. (2023) · Digestive Diseases · doi:10.1159/000529023 · Cited by 20
Role of exosomes in hepatocellular carcinoma and the regulation of traditional Chinese medicine
Yao, M., Liang, S., & Cheng, B. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1110922 · Cited by 20
“Tyrosine kinase inhibitors (TKIs), including sorafenib, lenvatinib and donafenib are still the first line drugs for advanced HCC, especially for those patients that could not benefit from atezolizumab plus bevacizumab treatment (Bruix et al., 2021; Reig et al., 2022).”
Background
Adjuvant therapy following curative treatments for hepatocellular carcinoma: current dilemmas and prospects
Guo, B., Chen, Q., Liu, Z., Chen, X., & Zhu, P. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1098958 · Cited by 22
“Curative surgery is the ideal treatment protocol for patients with HCC (3, 4), and the choice of surgical indications for liver resection (LR) varies between regions based on different administrative medical evidence.”
BackgroundMethod
Optimal treatment for small HCC (<3 cm): Resection, liver transplantation, or locoregional therapy?
Wu, X. J., Lokken, R. P., & Mehta, N. J. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100781 · Cited by 20
“Based on the LEGACY results, the most recent BCLC guidelines now suggest TARE as well as TACE as alternatives when ablation is not feasible.(13) In 2022, the RASER trial (single-centre, single-arm) investigated RS as a curative treatment for unresectable, single HCC <3 cm.”
Method
Intratumoral Immunotherapy: Is It Ready for Prime Time?
Ghosn, M., Tselikas, L., Champiat, S., Deschamps, F., Bonnet, B., Carre, É., Testan, M., Danlos, F., Farhane, S., Susini, S., et al. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01422-4 · Cited by 19
Is the CRAFITY score a superior predictor of prognosis and adverse events in hepatocellular carcinoma patients treated with locoregional-immunotherapy?
Guan, R., Mei, J., Lin, W., Deng, M., Li, S., & Guo, R. (2023) · Hepatology International · doi:10.1007/s12072-023-10535-8 · Cited by 20
“Systemic treatment and locoregional ther‐ apy are the preferred options for intermediate‐advanced cases [3, 4].”
Background
Vascular Normalization Caused by Short-Term Lenvatinib Could Enhance Transarterial Chemoembolization in Hepatocellular Carcinoma
Tachiiri, T., Nishiofuku, H., Maeda, S., Sato, T. A., Toyoda, S., Matsumoto, T., Chanoki, Y., Minamiguchi, K., Taiji, R., Kunichika, H., et al. (2023) · Current Oncology · doi:10.3390/curroncol30050360 · Cited by 20
“From these findings, we will propose that short-term lenvatinib prior to cTACE could become a standardized procedure in unresectable HCC.”
BackgroundInfluential
Intraprocedural assessment of ablation margins using computed tomography co-registration in hepatocellular carcinoma treatment with percutaneous ablation: IAMCOMPLETE study
Hendriks, P., van Dijk, K. M., Boekestijn, B., Broersen, A., Vreugd, J. J. V. D.-D., Coenraad, M. J., Tushuizen, M. E., van Erkel, A. R., van der Meer, R. W., van Rijswijk, C. S., et al. (2023) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2023.07.002 · Cited by 20
Decreased B4GALT1 promotes hepatocellular carcinoma cell invasiveness by regulating the laminin-integrin pathway
Chen, P., Liao, Y.-Y., Cheng, Y., Wu, H., Wu, Y., & Huang, M. (2023) · Oncogenesis · doi:10.1038/s41389-023-00494-y · Cited by 20
“Thus, approximately 80% of patients with HCC do not undergo curative treatment [3].”
Real-World Systemic Treatment Patterns after Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma in the United States
Singal, A. G., Özgürdal, K., Fan, X., Vassilev, Z. P., Pan, X., Multani, J. K., Chen, C., Zhou, Z., He, J., & Pisa, F. E. (2023) · Cancers · doi:10.3390/cancers15235532 · Cited by 20
“RW populations tend to have higher comorbidities, a worse performance status, and greater liver dysfunction than the well-selected patient populations in clinical trials [29–31].”
BackgroundSelf-citation
Application of artificial intelligence in the diagnosis of hepatocellular carcinoma
Koh, B., Danpanichkul, P., Wang, M., Tan, D. J. H., & Ng, C. H. (2023) · eGastroenterology · doi:10.1136/egastro-2023-100002 · Cited by 20
Thermal ablation of hepatocellular carcinoma
Crocetti, L., Scalise, P., Bozzi, E., Candita, G., & Cioni, R. (2023) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.13613 · Cited by 20
“44 A meta-analysis of randomized controlled trials comparing resection and RF ablation in patients with HCC within Milan criteria showed similar results in terms of 1-and 3-year survival rates.”
BackgroundResultInfluential
Defining Minimum Treatment Parameters of Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma: An Expert Consensus
Yanagihara, T. K., Tepper, J. E., Moon, A. M., Barry, A. S., Mollà, M., Seong, J., Torres, F., Apisarnthanarax, S., Buckstein, M. H., Cardenes, H. R., et al. (2024) · Practical Radiation Oncology · doi:10.1016/j.prro.2023.08.016 · Cited by 20
Self-citation
Prognostic Nutritional Index as a Prognostic Factor for Very Early-Stage Hepatocellular Carcinoma
Ho, C.-T., Tan, E. C., Lee, P., Chu, C., Huang, Y., Huo, T., Hou, M., Wu, J., & Su, C. (2024) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000678 · Cited by 25
CT-guided High-Dose-Rate Brachytherapy versus Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma
Auer, T. A., Müller, L., Schulze, D., Anhamm, M., Bettinger, D., Steinle, V., Haubold, J., Zopfs, D., dos Santos, D. P., Eisenblätter, M., et al. (2024) · Radiology · doi:10.1148/radiol.232044 · Cited by 20
Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti–PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A treatment with Chinese characteristics
Wu, J., Wu, J., Li, S., Luo, M., Zeng, Z., Li, Y., Fu, Y., Li, H., Liu, D.-Y., Ou, X.-Y., et al. (2024) · BioScience Trends · doi:10.5582/bst.2023.01326 · Cited by 20
Comparison of survival benefit and safety between surgery following conversion therapy versus surgery alone in patients with surgically resectable hepatocellular carcinoma at CNLC IIb/IIIa stage: a propensity score matching study
Ma, Z., Xiao, Z., yin, P., Wen, K., Wang, W., Yan, Y., Lin, Z., Li, Z., Wang, H., Zhang, J., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001193 · Cited by 20
“Clinical guidelines from the National Comprehensive Cancer Network (NCCN) and the Barcelona Cancer Liver Clinic (BCLC) staging system recommend non-surgical therapies based on systemic or local treatment for such patients [5,6] .”
Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma
Pang, B., Zuo, B., Huang, L., You, X., Liu, T., Hao, J., Yuan, C., Yang, C., Lau, W. Y., & Zhang, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112492 · Cited by 20
Deep learning-based 3D quantitative total tumor burden predicts early recurrence of BCLC A and B HCC after resection
Wei, H., Zheng, T., Zhang, X., Zheng, C., Jiang, D., Wu, Y., Lee, J. M., Bashir, M. R., Lerner, E., Liu, R., et al. (2024) · European Radiology · doi:10.1007/s00330-024-10941-y · Cited by 20
Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy
Saeki, I., Shimose, S., Tomonari, T., Ito, T., Tani, J., Takeuchi, Y., Yoshioka, N., Naito, T., Takeuchi, M., Kakizaki, S., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0311084 · Cited by 20
Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review
Manjunatha, N., Ganduri, V., Rajasekaran, K., Duraiyarasan, S., & Adefuye, M. A. (2022) · Cureus · doi:10.7759/cureus.28439 · Cited by 20
Hepatocellular carcinoma immune microenvironment and check point inhibitors-current status
Gupta, T., & Jarpula, N. S. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i3.353 · Cited by 19

Authors: Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., Sangro, B., Singal, A. G., Vogel, A., Fuster, J., Ayuso, C., & Bruix, J.
Affiliations: Hospital Clínic de Barcelona (ES)
University of California, San Francisco (US)
University Medical Center of the Johannes Gutenberg University Mainz (DE)
University of Milan (IT)
Northwestern University (US)
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
The University of Texas Southwestern Medical Center (US)
Medizinische Hochschule Hannover (DE)
Corresponding author: Bruix, Jordi
ORCID: Reig, Maria
Forner, Alejandro
Rimola, Jordi
Burrel, Marta
Garcia-Criado, Ángeles
Kelley, Robin K.
Galle, Peter R.
Mazzaferro, Vincenzo
Salem, Riad
Sangro, Bruno
Singal, Amit G.
Vogel, Arndt
Fuster, Josep
Ayuso, Carmen
Bruix, Jordi
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2022-03
Volume: 76
Issue: 3
Pages: 681-693
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2021.11.018
PMC: PMC8866082
OpenAlex: W3213277274
Cited by: 4,319
References: 136
Citations by year: 2026: 684 · 2025: 1071 · 2024: 1166 · 2023: 962 · 2022: 424
FWCI: 83.72
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Journal of Hepatology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
eScholarship (California Digital Library) (submittedVersion)
Funders: Fundación Científica de la Asociación Española Contra el Cáncer (PI044031)
National Institutes of Health (R01 R01 MD012565, PI18/00768)
Horizon 2020 Framework Programme (952103)
Instituto de Salud Carlos III (AC16/00065, PI18/0358, PI15/00145, PI18/00542, PI19/00742, PI18/00768)
European Association for the Study of the Liver
Horizon 2020
Topics: Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Keywords: hepatocellular carcinoma, Barcelona Clinic Liver Cancer staging, outcome prediction, treatment guidelines, evidence-based clinical decision-making
MeSH terms: Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Neoplasm Staging, Prognosis, Severity of Illness Index

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks